by Richard Cruse | Oct 19, 2022 | News
The patented process to make low-cost treatment for Haemophilia A, developed by Scottish biotechnology company ProFactor Pharma Ltd (PFP), has taken an important step closer to market. The successful completion of a Product Development, Technology Transfer and...
by Richard Cruse | Sep 20, 2022 | News
ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...
by Richard Cruse | Jan 26, 2023 | News
ProFactor Pharma’s executive directors, Jaymin Amin, CEO, and Richard Cruse, CFO, visited PT Bio Farma (Persero) (BFI) who recently licensed PFP’s patented process to make low-cost Factor VIII treatment for Haemophilia A. Jaymin met with BFI’s CEO, Mr. Honesti Basyir,...
by Richard Cruse | Nov 24, 2021 | News
Published on November 23, 2021 By Deborah Johnson Interview: Ending the haemophilia drug shortage Jaymin Amin, CEO of ProFactor Pharma (PFP), discusses the company’s life-changing, and lifesaving, work. PFP says it has developed a low-cost production process for...
by Richard Cruse | Mar 31, 2021 | News
ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and Eurasian Patent No 529615EA. This patent...
by Richard Cruse | Jan 31, 2021 | News
Scottish biotech business ProFactor Pharma Ltd: (PFP) has completed the optimisation of its process for the manufacture of recombinant Factor VIII, for the treatment of Haemophilia A. In July 2020 we reported on the important development milestone that had been...
by Richard Cruse | Jan 19, 2021 | News
A year on from my last analysis of the World Federation for Hemophilia (WFH) Report on the Annual Survey we see in 2019 a further improvement in the number of people treated. However, we also see new data on the prevalence of the haemophilia A which suggests there are...
by Richard Cruse | Jul 15, 2020 | News
ProFactor Pharma Ltd (PFP), has completed an important development milestone in its programme to transform the treatment of ‘Haemophilia A’. The company has now received the second tranche of funding from its £2m funding round announced in September 2019 to advance...
by Richard Cruse | Jan 26, 2020 | News
We have been analysing the data provided by the World Federation for Hemophilia (WFH) for a number of years to develop our understanding of the market. Its Reports on the Annual Survey give details of the number of patients by country and the quantity of FVIII used....
by Richard Cruse | Nov 15, 2019 | News
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...
